Abstract
Mass spectrometry information has long offered the potential of discovering biomarkers that would enable clinicians to diagnose disease, and treat it with targeted therapies. PeptideAtlas currently provides access to large-scale spectra data and identification information. This data, and the generation of targeted peptide information, represents the first step in the process of locating disease biomarkers. Reaching the goal of clinical proteomics requires that this data be integrated with additional information from disease literature and genomic studies. Here we describe PeptideAtlas and associated methods for mining the data, as well as the software tools necessary to support large-scale integration and mining.
Keywords: SRM, Mass spectrometry, proteomic, visualization, data mining, PeptideAtlas, Streptococcus pyogenes, Glioblastoma, Integration, Cytoscape
Current Pharmaceutical Design
Title: Mining PeptideAtlas for Biomarkers and Therapeutics in Human Disease
Volume: 18 Issue: 6
Author(s): Sarah Killcoyne, Eric W. Deutsch and John Boyle
Affiliation:
Keywords: SRM, Mass spectrometry, proteomic, visualization, data mining, PeptideAtlas, Streptococcus pyogenes, Glioblastoma, Integration, Cytoscape
Abstract: Mass spectrometry information has long offered the potential of discovering biomarkers that would enable clinicians to diagnose disease, and treat it with targeted therapies. PeptideAtlas currently provides access to large-scale spectra data and identification information. This data, and the generation of targeted peptide information, represents the first step in the process of locating disease biomarkers. Reaching the goal of clinical proteomics requires that this data be integrated with additional information from disease literature and genomic studies. Here we describe PeptideAtlas and associated methods for mining the data, as well as the software tools necessary to support large-scale integration and mining.
Export Options
About this article
Cite this article as:
Killcoyne Sarah, W. Deutsch Eric and Boyle John, Mining PeptideAtlas for Biomarkers and Therapeutics in Human Disease, Current Pharmaceutical Design 2012; 18 (6) . https://dx.doi.org/10.2174/138161212799277833
DOI https://dx.doi.org/10.2174/138161212799277833 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Integrated Application of Enhanced Replacement Method and Ensemble Learning for the Prediction of BCRP/ABCG2 Substrates
Current Bioinformatics Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success
Current Cancer Therapy Reviews Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Editorial: The microRNA 221/222 Cluster: Inaugurating a New Era in Cardiovascular Disease and Cancer?
Current Vascular Pharmacology Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Kinase Inhibitor Conjugates
Current Pharmaceutical Design Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery Hydroxy Cinnamic Acid Derivatives as Partial PPARγ Agonists: In silico Studies, Synthesis and Biological Characterization Against Chronic Myeloid Leukemia Cell Line (K562)
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Inflammatory Bowel Disease and Inflammation-Associated Colon Cancer:Partners in Crime Guest Editor: Silvio Danese ]
Current Drug Targets Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer Strategies
Anti-Cancer Agents in Medicinal Chemistry Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy